Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.43 |
| ▸ | CETP | P11597 | 12/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207160 | 0.89 | CETP (0.39) | CETP | |
| SCHEMBL3221198 | 0.86 | CETP (0.41) | CETP | |
| SCHEMBL3205200 | 0.86 | SGMS2 (0.40) | CETP | |
| SCHEMBL3198681 | 0.85 | CETP (0.39) | CETP | |
| SCHEMBL13491317 | 0.85 | CETP (0.39) | CETP | |
| SCHEMBL4220331 | 0.85 | CETP (0.37) | GLSCETP | |
| SCHEMBL3201375 | 0.85 | CETP (0.41) | CETP | |
| SCHEMBL13491322 | 0.82 | CETP (0.38) | CETP | |
| SCHEMBL3209856 | 0.82 | CETP (0.38) | CETP | |
| SCHEMBL3217676 | 0.82 | CETP (0.40) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041705-A1 | Organic Compounds | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041705-A1 | Organic Compounds | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| US-20100041705-A1 | Organic Compounds | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
| WO-2008058961-A1 | HETEROCYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041705-A1 | Organic Compounds | CETP, NPC1, LCAT | GLS 4160/4885CETP 1/4885HDAC6 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.